Utilización de bevacizumab en las complicaciones neurológicas durante el tratamiento inicial de los gliomas malignos

Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med., 352, 987, 10.1056/NEJMoa043330 González, 2007, Effect of bevacizumab on radiation necrosis of the brain, Int J Radiat Oncol Biol Phys., 67, 323, 10.1016/j.ijrobp.2006.10.010 Batchelor, 2007, AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients, Cancer Cell., 11, 83, 10.1016/j.ccr.2006.11.021 Zuniga, 2009, Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan, J Neurooncol., 91, 329, 10.1007/s11060-008-9718-y Vredenburgh, 2007, Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma, Clin Cancer Res., 13, 1253, 10.1158/1078-0432.CCR-06-2309 Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol., 27, 4733, 10.1200/JCO.2008.19.8721 Hurwitz, 2004, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer, N Engl J Med., 350, 2335, 10.1056/NEJMoa032691 Johnson, 2004, Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer, J Clin Oncol., 22, 2184, 10.1200/JCO.2004.11.022 Miller, 2007, Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer, N Engl J Med., 357, 2666, 10.1056/NEJMoa072113 Yang, 2003, A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer, N Engl J Med., 349, 427, 10.1056/NEJMoa021491